I feel more regular. I have more energy, better skin, better hair.
For sixteen years, a young man in Michigan measured time by monthly blood transfusions — a rhythm imposed on him by sickle cell disease before he had the language to question it. In December 2025, Chantez Sanford Jr. became the first person in Michigan to receive Lyfgenia gene therapy at Children's Hospital of Michigan, a treatment that repairs a patient's own stem cells rather than borrowing someone else's. His recovery signals not merely a medical milestone but a quiet reckoning with what it means to inherit suffering and then, at last, to have it rewritten.
- Sanford spent sixteen years enduring monthly blood transfusions, stunted growth, and unpredictable hospitalizations — a life organized entirely around a disease that offered no pause.
- Without a matched bone marrow donor, a conventional cure was out of reach, leaving his family listening for any signal from the medical world that something else might be possible.
- The FDA's 2023 approval of Lyfgenia opened a new path: a therapy that collects a patient's own stem cells, adds a gene for healthy hemoglobin production, and returns them — no donor required.
- On December 2, 2025, Sanford received the treatment and within weeks reported concrete, visible improvements — more energy, clearer eyes, healthier skin, and an end to monthly transfusions.
- Children's Hospital of Michigan is already preparing a second patient, suggesting this breakthrough is moving from singular milestone toward a broader standard of care for sickle cell patients across the state.
Chantez Sanford Jr. was eight years old when monthly blood transfusions became a fixture of his life. Sickle cell disease had bent his red blood cells into rigid, sickle-shaped forms that clogged his veins, triggered fevers, and quietly stunted his growth while his peers moved on without him. His mother watched her son spend his childhood in hospital rooms. Still, Sanford found a way to build something resembling a regular life — enrolling at Savannah College of Art and Design to study 3-D animation, learning to carry his illness without letting it become his only identity.
A bone marrow transplant could have offered a cure, but it required a matched donor. His brother wasn't one. So his family waited, and when whispers of an FDA approval began circulating, his mother paid close attention. In December 2023, those whispers became real: the FDA approved Lyfgenia, a gene therapy that collects a patient's own blood stem cells, introduces a gene enabling healthy hemoglobin production, and returns the modified cells to the body — a repair from within rather than a gift from outside.
Sanford moved quickly. His stem cells were collected in the summer of 2025, and on December 2 of that year, he received the treatment at Children's Hospital of Michigan — the first patient in the state to do so. The changes that followed were modest in description but profound in meaning: more energy, clearer eyes, healthier skin and hair, urine that no longer signaled distress. No more monthly transfusions. No more the quiet, constant exhaustion of a body at war with itself.
The hospital's medical director called it a very good outcome. A second patient is already being prepared for the same therapy, pointing toward a future where what Sanford experienced first might eventually reach others in Michigan who have spent their lives, as he did, waiting for relief.
Chantez Sanford Jr. spent sixteen years of his life walking into Children's Hospital of Michigan once a month for a blood transfusion. He was eight years old when the routine began, and by the time he turned twenty-four, the rhythm of needles and bags of blood had become as familiar as school or sleep. Sickle cell disease had shaped everything about his body—the way his red blood cells twisted into rigid, sickle-shaped forms that clogged his veins, the fevers that sent him to the hospital, the growth that never quite caught up to his peers. His mother watched her son's development stall, watched him spend his childhood in hospital rooms instead of playgrounds.
Yet Sanford managed something that might have seemed impossible: he built a regular life anyway. He enrolled at Savannah College of Art and Design to study 3-D animation. He learned to talk about his disease without letting it become his entire story. "Spending time in the hospital frequently for blood transfusions and getting sick often—it's just a confusing feeling," he said later. "But I did have a pretty regular childhood, despite the sickle cell."
The disease itself is straightforward in its cruelty. Sickle cell is inherited, passed down through genes. In healthy people, red blood cells are round and flexible, moving easily through veins. In people with sickle cell, those cells become hard and curved, like the farming tool they're named after. They jam up inside blood vessels, blocking the flow of oxygen-rich blood to organs and tissue. The result is pain, organ damage, stroke risk, and a lifetime of medical management. For Sanford, it meant transfusions every month, fevers that spiked without warning, episodes of pain that sent him back to the hospital again and again.
A bone marrow transplant can cure sickle cell disease, but only if a matched donor exists. Sanford's brother was not a match. So his family waited, and his mother listened for news from the medical world. "A couple of years ago, we heard whispers the FDA had something they were going to approve," Tamara Sanford said. That whisper became real in December 2023, when the FDA approved a drug called Lyfgenia. The treatment works by collecting a patient's own blood stem cells, adding a gene that helps the body produce healthy hemoglobin, and then returning those modified cells to the patient's body. It's not a transplant from someone else—it's a repair of your own cells, sent back to do the work they should have been doing all along.
Sanford didn't hesitate. In the summer of 2025, doctors collected his stem cells. On December 2, 2025, he received the treatment at Children's Hospital of Michigan, becoming the first patient in the state to undergo this particular therapy. The hospital's medical team began tracking his progress through blood tests and hemoglobin levels, watching for the complications that had defined his life to either persist or fade.
They faded. Within weeks, Sanford noticed changes that seemed almost mundane until you understood what they meant. "I feel more regular," he said. "I have more energy, my urine is a better color, I have white eyes, better skin, better hair." These weren't poetic observations—they were the concrete markers of a body that was finally working the way it was supposed to. No more monthly transfusions. No more the constant low-level exhaustion that comes from cells that can't carry oxygen properly. No more the visible signs of chronic illness written across his skin and eyes.
Süreyya Savaşan, the medical director of the Transplantation and Cell Therapy Program at Children's Hospital of Michigan, called it a very good outcome. The hospital is already preparing a second sickle cell patient for the same treatment, moving toward a future where this therapy might become available to more people in Michigan who have spent their lives, like Sanford did, waiting for their bodies to stop fighting them.
Notable Quotes
Spending time in the hospital frequently for blood transfusions and getting sick often—it's just a confusing feeling. But I did have a pretty regular childhood, despite the sickle cell.— Chantez Sanford Jr.
We are very excited about Chantez and the opportunity for other sickle cell disease patients to be free of ongoing transfusions and awful side effects from this heinous disease.— Süreyya Savaşan, medical director of Transplantation and Cell Therapy Program at Children's Hospital of Michigan
The Hearth Conversation Another angle on the story
What does it actually feel like, living with sickle cell before treatment? Is it constant pain, or does it come in waves?
It's both. You have the baseline exhaustion from cells that don't work right—that's always there. Then you have the acute episodes, the fevers and the pain that send you to the hospital. For Sanford, it meant a transfusion every single month for sixteen years. That's not just medical—that's your entire childhood organized around a hospital schedule.
And the gene therapy—does it actually cure the disease, or does it just manage it better?
It's closer to a cure than anything else available. The therapy modifies his own stem cells to produce healthy hemoglobin, so his body is essentially fixing itself at the cellular level. He's not dependent on transfusions anymore. That's a fundamental change, not just symptom management.
Why didn't he get a bone marrow transplant earlier if that's also a cure?
Because bone marrow transplants require a matched donor, and his brother wasn't a match. You can't just use anyone's marrow—the immune system has to accept it. Gene therapy sidesteps that problem entirely by using his own cells.
What happens now? Is he cured permanently?
The early signs are very good. His energy is back, his skin and hair improved, his blood markers are better. But this is still relatively new—Lyfgenia was only approved in 2023. The hospital is watching him closely and preparing other patients for the same treatment. The real question is whether this holds over years and decades.
How many other people in Michigan have sickle cell disease?
The source doesn't give a number, but sickle cell affects thousands of people in Michigan alone. What matters is that Sanford is the first to access this particular therapy in the state. That opens a door for others.